Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Leibowitz

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Journal of Medicinal Chemistry|June 13, 2003
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetesP Y Michellys, R J Ardecky, J H Chen, et al.
Leukemia|August 1, 2019
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosisJ Mascarenhas, H Kosiorek, J Prchal, et al.
Endocrinology|November 5, 2005
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetesMark D Leibowitz, Robert J Ardecky, Marcus F Boehm, et al.
Cell Reports|July 28, 2021
A pan-cancer organoid platform for precision medicineBrian M Larsen, Madhavi Kannan, Lee F Langer, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Journal of Medicinal Chemistry|June 13, 2003
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetesP Y Michellys, R J Ardecky, J H Chen, et al.
Leukemia|August 1, 2019
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosisJ Mascarenhas, H Kosiorek, J Prchal, et al.
Endocrinology|November 5, 2005
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetesMark D Leibowitz, Robert J Ardecky, Marcus F Boehm, et al.
Cell Reports|July 28, 2021
A pan-cancer organoid platform for precision medicineBrian M Larsen, Madhavi Kannan, Lee F Langer, et al.
Pageof 10